Department of Surgery, Hartford Hospital, Hartford, CT, USA.
Cancer Institute, Hartford HealthCare, Hartford, CT, USA.
J Hosp Infect. 2021 Aug;114:117-125. doi: 10.1016/j.jhin.2021.04.021. Epub 2021 Apr 27.
Healthcare workers (HCWs) are at the front line of the ongoing coronavirus 2019 (COVID-19) pandemic. Comprehensive evaluation of the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among HCWs in a large healthcare system could help to identify the impact of epidemiological factors and the presence of symptoms on the immune response to the infection over time.
To determine the seroprevalence of SARS-CoV-2-specific antibodies among HCWs, identify associated epidemiological factors and study antibody kinetics.
A longitudinal evaluation of the seroprevalence and epidemiology of SARS-CoV-2-specific antibodies was undertaken in approximately 30,000 HCWs in the largest healthcare system in Connecticut, USA.
At baseline, the prevalence of SARS-CoV-2 antibody among 6863 HCWs was 6.3% [95% confidence interval (CI) 5.7-6.9%], and was highest among patient care support (16.7%), medical assistants (9.1%) and nurses (8.2%), and lower for physicians (3.8%) and advanced practice providers (4.5%). Seroprevalence was significantly higher among African Americans [odds ratio (OR) 3.26 compared with Caucasians, 95% CI 1.77-5.99], in participants with at least one symptom of COVID-19 (OR 3.00, 95% CI 1.92-4.68), and in those reporting prior quarantine (OR 3.83, 95% CI 2.57-5.70). No symptoms were reported in 24% of seropositive participants. Among the 47% of participants who returned for a follow-up serological test, the seroreversion rate was 39.5% and the seroconversion rate was 2.2%. The incidence of re-infection in the seropositive group was zero.
Although there is a decline in the immunoglobulin G antibody signal over time, 60.5% of seropositive HCWs had maintained their seroconversion status after a median of 5.5 months.
医护人员(HCWs)处于正在进行的 2019 年冠状病毒病(COVID-19)大流行的前线。对大型医疗系统中 HCWs 中严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的血清流行率进行综合评估,有助于确定随着时间的推移,流行病学因素和症状的存在对感染免疫反应的影响。
确定 HCWs 中 SARS-CoV-2 特异性抗体的血清流行率,确定相关的流行病学因素并研究抗体动力学。
在美国康涅狄格州最大的医疗系统中,对大约 30,000 名 HCWs 进行了 SARS-CoV-2 特异性抗体的血清流行率和流行病学的纵向评估。
在基线时,6863 名 HCWs 中 SARS-CoV-2 抗体的流行率为 6.3%[95%置信区间(CI)为 5.7-6.9%],在患者护理支持人员(16.7%)、医疗助理(9.1%)和护士(8.2%)中最高,而在医生(3.8%)和高级执业医师(4.5%)中较低。非裔美国人的血清流行率明显更高[与白种人相比,比值比(OR)为 3.26,95%CI 为 1.77-5.99],至少有 COVID-19 一种症状的参与者(OR 为 3.00,95%CI 为 1.92-4.68)和报告先前隔离的参与者(OR 为 3.83,95%CI 为 2.57-5.70)。24%的血清阳性参与者没有报告任何症状。在 47%返回进行随访血清学检测的参与者中,血清转化率为 39.5%,血清转阳率为 2.2%。在血清阳性组中,再感染的发生率为零。
尽管随着时间的推移,免疫球蛋白 G 抗体信号有所下降,但在中位数为 5.5 个月后,60.5%的血清阳性 HCWs 仍保持血清转化状态。